aTYR PHARMA Income Statement (2019-2025) | ATYR

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.09M0.18M0.14M8.06M0.19M0.15M2.05M10.39M0.35M0.23M0.19M
Operating items
Research & Development 3.31M3.80M3.59M3.62M4.36M4.62M4.70M8.90M9.87M14.91M9.38M9.84M10.32M12.76M13.36M13.97M14.81M12.23M11.81M15.38M22.13M
Selling, General & Administrative 2.42M1.88M2.52M2.59M2.15M2.04M2.29M3.48M3.62M3.43M3.41M3.72M2.65M3.20M3.51M3.34M3.34M3.59M3.96M4.93M4.80M
Restructuring Costs 2.92M2.76M2.80M2.93M3.06M3.93M3.89M
Other Operating Expenses -2.92M-2.76M-2.80M-2.93M-3.06M-3.93M-3.89M
Operating Expenses 5.74M5.68M6.11M6.21M6.51M6.66M6.99M12.38M13.49M18.34M12.79M13.56M12.97M15.96M16.87M17.32M18.14M15.82M15.77M20.31M26.93M
Operating Income -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
EBIT -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
Non-operating items
Non Operating Income -0.21M-0.15M-0.17M-0.11M-0.13M-0.09M0.01M0.22M0.25M0.43M0.83M1.22M1.27M1.20M1.15M1.01M0.88M0.85M0.89M0.78M1.00M
Net income details
EBT -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
Profit After Tax -5.85M-5.64M-5.97M1.75M-6.45M-6.60M-4.93M-12.15M-13.24M-7.52M-11.95M-12.34M-11.34M-14.76M-15.49M-16.31M-17.26M-14.97M-14.90M-19.53M-25.75M
Income from Non-Controlling Interests -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Income from Continuing Operations -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
Consolidated Net Income -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
Income towards Parent Company -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
Net Income towards Common Stockholders -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M
Additional items
EPS (Basic) -1.80-1.47-1.780.25-0.69-0.68-0.46-0.44-0.46-0.26-0.29-0.22-0.20-0.25-0.23-0.23-0.23-0.21-0.17-0.22-0.26
EPS (Weighted Average and Diluted) 0.25-0.54-0.44-0.46-0.26-0.29-0.22-0.20-0.25-0.23-0.23-0.23-0.21-0.17-0.22-0.26
Shares Outstanding (Weighted Average) 2.42M3.24M3.85M3.36M6.88M9.36M9.65M9.16M14.10M16.13M18.16M19.08M27.82M28.06M28.66M28.42M41.90M55.14M57.89M53.61M66.08M72.28M75.80M74.26M86.49M90.12M97.15M
Shares Outstanding (Diluted Average) 2.42M6.88M9.16M14.10M16.13M18.16M19.08M27.82M28.06M28.66M28.42M41.90M55.14M57.89M53.61M66.08M72.28M75.80M74.26M86.49M90.12M97.15M
EBITDA -5.64M-5.50M-5.96M1.86M-6.32M-6.51M-4.94M-12.38M-13.49M-7.95M-12.79M-13.56M-12.62M-15.96M-16.64M-17.32M-18.14M-15.82M-15.77M-20.31M-26.75M